First efficacy trial of Athersys stem cell therapy yields disappointing interim results. So what now?
Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis. But the company isn’t too worried about what that might mean just yet. Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 […]